Abstract：Objective To study the clinical characteristics and genetic variation of early-onset Charcot-Marie-Tooth disease (CMT). Methods Children with a clinical diagnosis of early-onset CMT were selected for the study. Relevant clinical data were collected, and electromyogram and CMT-related gene detection were performed and analyzed. Results A total of 13 cases of early-onset CMT were enrolled, including 9 males (69%) and 4 females (31%). The mean age at consultation was 4.0±2.1 years. Among them, 12 children (92%) had an age of onset less than 2 years, 9 children (69%) were diagnosed with CMT type 1 (including 6 cases of Dejerine-Sottas syndrome), 1 child (8%) with intermediate form of CMT, and 3 children (23%) with CMT type 2. The genetic test results of these 13 children showed 6 cases (46%) of PMP22 duplication mutation, 3 cases (23%) of MPZ gene insertion mutation and point mutation, 3 cases (23%) of MFN2 gene point mutation, and 1 case (8%) of NEFL gene point mutation. Eleven cases (85%) carried known pathogenic mutations and 2 cases (15%) had novel mutations. The new variant c.394C > G (p.P132A) of the MPZ gene was rated as "possibly pathogenic" and the new variant c.326A > G (p.K109R) of the MFN2 gene was rated as "pathogenic". Conclusions Early-onset CMT is mainly caused by PMP22 gene duplication mutation and MPZ gene mutations. The clinical phenotype is mainly CMT type 1, among which Dejerine-Sottas syndrome accounts for a considerable proportion.
Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease[J]. Clin Genet, 1974, 6(2):98-118.
[2]
Gutmann L, Shy M. Update on Charcot-Marie-Tooth disease[J]. Curr Opin Neurol, 2015, 28(5):462-467.
[3]
Timmerman V, Strickland AV, Züchner S. Genetics of Charcot-Marie-Tooth (CMT) disease within the frame of the Human Genome Project success[J]. Genes (Basel), 2014, 5(1):13-32.
[4]
DiVincenzo C, Elzinga CD, Medeiros AC, et al. The allelic spectrum of Charcot-Marie-Tooth disease in over 17,000 individuals with neuropathy[J]. Mol Genet Genomic Med, 2014, 2(6):522-529.
[5]
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants:a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5):405-424.
[6]
Chung KW, Kim SB, Park KD, et al. Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2(MFN2) mutations[J]. Brain, 2006, 129(Pt 8):2103-2118.
Santel A, Fuller MT. Control of mitochondrial morphology by a human mitofusin[J]. J Cell Sci, 2001, 114(Pt 5):867-874.
[9]
Rojo M, Legros F, Chateau D, et al. Membrane topology and mitochondrial targeting of mitofusins, ubiquitous mammalian homologs of the transmembrane GTPase Fzo[J]. J Cell Sci, 2002, 115(Pt 8):1663-1674.
[10]
Cornett KMD, Menezes MP, Shy RR, et al. Natural history of Charcot-Marie-Tooth disease during childhood[J]. Ann Neurol, 2017, 82(3):353-359.
[11]
Abe A, Numakura C, Kijima K, et al. Molecular diagnosis and clinical onset of Charcot-Marie-Tooth disease in Japan[J]. J Hum Genet, 2011, 56(5):364-368.
[12]
Gabreëls-Festen A. Dejerine-Sottas syndrome grown to maturity:overview of genetic and morphological heterogeneity and follow-up of 25 patients[J]. J Anat, 2002, 200(4):341-356.
[13]
Kim YH, Chung HK, Park KD, et al. Comparison between clinical disabilities and electrophysiological values in Charcot-Marie-Tooth 1A patients with PMP22 duplication[J]. J Clin Neurol, 2012, 8(2):139-145.
[14]
Hattori N, Yamamoto M, Yoshihara T, et al. Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32):a clinicopathological study of 205 Japanese patients[J]. Brain, 2003, 126(Pt 1):134-151.
